海松被投企业| Teon Therapeutics完成3000万美元A轮融资

编者按：本文来自微信公众号“海松资本”（ID:Oceanpine_Capital），作者：深耕硬核科技的，36氪经授权发布。

信息源自：Teon Therapeutics Inc.翻译：海松资本

2021年2月23日，据美通社报道，专注于研发免疫通路中GPCR 靶点的小分子药物的肿瘤免疫新药研发公司——Teon Therapeutics，宣布完成3,000万美元的A轮融资。本轮融资由海松资本（Oceanpine Capital）领投，元禾谷风资本（Oriza Ventures），Lifespan Investments以及前Gilead高管参投，原股东北极光创投（Northern Light Venture Capital）、凯泰资本和东方富海继续加持。

本轮融资主要用于加速公司的A2BR靶点的选择性拮抗剂TT-702进入临床，以及推进产品管线的研发。

Teon Therapeutics创始人兼首席执行官Lina Yao博士表示：“ Teon Therapeutics能够在市场环境不确定的情况下，超额完成本轮募资，充分映证了我们的管线研发潜力，同时也证明了我们为患者和投资者创造价值的信心。我们与著名非盈利组织英国癌症研究中心（CRUK）合作，推进A2BR靶点的选择性拮抗剂TT-702于今年进入临床，以及公司产品管线的研发。非常感谢新老股东的支持，与我们共同实现改善全世界癌症患者生活的愿景。”

作为本轮的领投方，海松资本CEO、管理合伙人陈立光先生表示：“ Teon Therapeutics下一代免疫疗法的进展非常快，令人非常惊喜。Teon Therapeutics专注于免疫通路中GPCR 靶点的小分子药物研发，与其他免疫肿瘤学疗法不同，数据显示，A2BR 在肿瘤细胞和免疫细胞上都表达，因此对肿瘤生长有双重作用。海松资本非常荣幸参与本次融资，并作为领投方支持Teon Therapeutics。同时，我们也非常期待与这支拥有资深行业经验的团队以及其他投资方合作，推动公司独特的癌症免疫疗法进入临床。”

北极光创投的创始管理合伙人邓锋先生表示：“我们很高兴能再次支持Teon Therapeutics的药物研发。北极光对公司经验丰富的创始团队和世界一流的GPCR专家充满信心，非常期待能与公司接下来的合作，支持快速开发和扩展其新疗法的产品线，尽早让更多的癌症患者受益。”

关于Teon Therapeutics

Teon Therapeutics 位于美国加州湾区，是一家专注于开发一系列在肿瘤微环境中调节代谢信号通路的小分子药物的创新药企，致力于研发针对免疫通路中GPCR 靶点的小分子药物，从而改善癌症患者的生活。目前公司有多个First-in-Class和 Best-in-Class的候选药物，进展最快的A2BR靶点的选择性拮抗剂TT-702将于2021年进入临床1b期 。其核心团队均来自美国TOP10跨国药企，具有在Gilead & Amgen平均20年的工作经验，拥有丰富的GPCR小分子药物及肿瘤领域早期研发经验。

以下为官方报道原文：

Teon Therapeutics Completes $30 Million Series A Financing

NEWS PROVIDED BY Teon Therapeutics, Inc. 

Feb 23, 2021, 10:38 ET

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/—Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing. The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives. All existing investors also participated in the financing round including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital. The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.

"This oversubscribed financing, during these uncertain times, validates the potential of our pipeline and reflects the confidence in our leadership team to deliver value for patients and investors. In collaboration with Cancer Research UK, we will advance our A2BR-selective antagonist TT-702 into the clinic later this year, and we will also strive to extend our unique portfolio." said Lina Yao, MD, Ph.D., Founder and Chief Executive Officer of Teon. "We are grateful for the continued support of our existing investors and are excited to welcome our new investors during this exciting time of growth and innovation for Teon. Their expertise will be invaluable as we execute on our vision to improve the lives of cancer patients across the world."

"The rapid development of Teon's next generation of immunotherapies has been very impressive." said Dave Chenn, Founder, CEO and Managing Partner at Oceanpine Capital. "Teon's GPCR-focused portfolio is differentiated from other immuno-oncology approaches as evidenced by targeting both immune and cancer cells. We look forward to working with this experienced team and other investors to advance a unique class of cancer immunotherapies into the clinic."

"We are thrilled for our continued partnership with Teon," said Feng Deng, Founding Managing Partner at Northern Light Venture Capital. "We have strong confidence in Teon's experienced team and world-class GPCR experts and looking forward to working closely together to rapidly develop and expand its pipeline of novel therapies so that it can benefit as many cancer patients as quickly as possible."

About Teon Therapeutics

Teon Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enter Phase1b trials in 2021. The experienced leadership team are experts in adenosine and GPCR therapeutics and were primary inventors of Lexiscan®, the only FDA-approved selective adenosine therapeutic, which contributed to the acquisition of CV Therapeutics by Gilead. Northern Light Venture Capital led the company's $7M Seed round. For more information about Teon Therapeutics, please visit: www.teontherapeutics.com